CeriBell, Inc. (NASDAQ:CBLL – Get Free Report) CTO Raymond Woo sold 4,887 shares of the firm’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $24.38, for a total value of $119,145.06. Following the transaction, the chief technology officer directly owned 203,118 shares of the company’s stock, valued at $4,952,016.84. This represents a 2.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Raymond Woo also recently made the following trade(s):
- On Tuesday, September 8th, Raymond Woo sold 4,887 shares of CeriBell stock. The stock was sold at an average price of $24.33, for a total transaction of $118,900.71.
- On Friday, August 21st, Raymond Woo sold 1,979 shares of CeriBell stock. The shares were sold at an average price of $24.02, for a total transaction of $47,535.58.
CeriBell Stock Performance
NASDAQ:CBLL opened at $23.69 on Monday. The company has a 50-day moving average of $22.78 and a 200-day moving average of $20.24. The firm has a market cap of $909.22 million, a price-to-earnings ratio of -13.46 and a beta of 0.94. The company has a current ratio of 9.18, a quick ratio of 8.79 and a debt-to-equity ratio of 0.16. CeriBell, Inc. has a twelve month low of $10.85 and a twelve month high of $25.63.
Institutional Investors Weigh In On CeriBell
Hedge funds and other institutional investors have recently made changes to their positions in the company. Strs Ohio bought a new stake in shares of CeriBell in the 1st quarter valued at approximately $27,000. Legal & General Group Plc bought a new position in CeriBell during the second quarter valued at approximately $53,000. Caitong International Asset Management Co. Ltd lifted its stake in CeriBell by 8,735.5% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,739 shares of the company’s stock valued at $60,000 after acquiring an additional 2,708 shares during the last quarter. State of Wyoming acquired a new stake in CeriBell in the first quarter valued at approximately $62,000. Finally, Quantbot Technologies LP bought a new stake in CeriBell in the second quarter worth approximately $112,000.
Wall Street Analyst Weigh In
A number of equities research analysts have recently issued reports on CBLL shares. Weiss Ratings lowered CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday. TD Cowen increased their price target on CeriBell from $29.00 to $33.00 and gave the company a “buy” rating in a research report on Friday. BTIG Research restated a “buy” rating and set a $30.00 price objective on shares of CeriBell in a report on Friday, September 11th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $29.00 price objective on shares of CeriBell in a research note on Thursday, September 3rd. Finally, Barclays raised shares of CeriBell to a “neutral” rating in a research report on Tuesday, August 18th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $27.00.
Get Our Latest Report on CeriBell
CeriBell Company Profile
CeriBell, Inc develops medical technology designed to make electroencephalography (EEG) more accessible in acute-care settings. Its primary product is the Ceribell Rapid Response EEG system, a portable, point-of-care platform that enables clinicians to record and assess brain activity at the bedside, including when evaluating patients for seizures and status epilepticus.
The Ceribell system combines a simplified EEG headband and recording device with software that supports rapid interpretation.
Featured Stories
- Five stocks we like better than CeriBell
- Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?
- The AI Buildout Needs Power It Cannot Get: 4 Energy Stocks Already Have It
- McDonald’s Is Undergoing a Massive New Growth Strategy. Can It Win Back Consumers?
- MGM Resorts Stock Sinks After Diller Deal Collapse: Overreaction or Warning?
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
